Whether the headlines describe a “cancer moonshot” or a “war on cancer,” they capture a yearning and determination to eliminate the scourge of malignancy. Artificial intelligence, huge genomic data sets, and expanded access to clinical trials are pushing forward knowledge about the package of diseases we call cancer. As the treatment arsenal expands, it highlights both the promise and the limits of immunotherapy, targeted drugs, and other advances. Broad-based funding across many scientific disciplines will most likely drive further progress, but is the hardest to secure. What is the latest in cancer treatment, and why are cures so elusive? (Underwritten by GSK)